Literature DB >> 9707162

Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety.

J C Ballenger1, J R Davidson, Y Lecrubier, D J Nutt, D S Baldwin, J A den Boer, S Kasper, M K Shear.   

Abstract

OBJECTIVE: To provide primary care clinicians with a better understanding of management issues in panic disorder and guide clinical practice with recommendations for appropriate pharmacotherapy. PARTICIPANTS: The 4 members of the International Consensus Group on Depression and Anxiety were James C. Ballenger (chair), Jonathan R. T. Davidson, Yves Lecrubier, and David J. Nutt. Four faculty invited by the chairman also participated: David S. Baldwin, Johan A. den Boer, Siegfried Kasper, and M. Katherine Shear. EVIDENCE: The consensus statement is based on the 6 review papers that are published in this supplement and on the scientific literature relevant to these issues. CONSENSUS PROCESS: There were group meetings held during a 2-day period. On day 1, the group discussed each review paper and the chairman and discussant (Dr. Kasper) identified key issues for further debate. On day 2, the group discussed these key issues to arrive at a consensus view. After the group meetings, the consensus statement was drafted by the chairman and approved by all attendees.
CONCLUSIONS: The consensus statement provides standard definitions for response and remission and identifies appropriate strategy for the management of panic disorder in a primary care setting. Serotonin selective reuptake inhibitors are recommended as drugs of first choice with a treatment period of 12 to 24 months. Pharmacotherapy should be discontinued slowly over a period of 4 to 6 months.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9707162

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  18 in total

1.  Algorithm for the pharmacotherapy of anxiety disorders.

Authors:  Dan J Stein
Journal:  Curr Psychiatry Rep       Date:  2003-08       Impact factor: 5.285

Review 2.  Animal models of anxiety disorders.

Authors:  Joachim D K Uys; Dan J Stein; Willie M U Daniels; Brian H Harvey
Journal:  Curr Psychiatry Rep       Date:  2003-08       Impact factor: 5.285

Review 3.  Interventions to improve management of anxiety disorders in general practice: a systematic review.

Authors:  Jantien Heideman; Eric van Rijswijk; Nieke van Lin; Sandra de Loos; Miranda Laurant; Michel Wensing; Eloy van de Lisdonk; Richard Grol
Journal:  Br J Gen Pract       Date:  2005-11       Impact factor: 5.386

Review 4.  Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.

Authors:  D P Figgitt; K J McClellan
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

Review 5.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  The Depression Anxiety Stress Scales (DASS): detecting anxiety disorder and depression in employees absent from work because of mental health problems.

Authors:  K Nieuwenhuijsen; A G E M de Boer; J H A M Verbeek; R W B Blonk; F J H van Dijk
Journal:  Occup Environ Med       Date:  2003-06       Impact factor: 4.402

7.  A Proposed Algorithm for Improved Recognition and Treatment of the Depression/Anxiety Spectrum in Primary Care.

Authors:  James C. Ballenger; Jonathan R. T. Davidson; Yves Lecrubier; David J. Nutt
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-04

8.  A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder.

Authors:  Mark Pollack; Richard Mangano; Richard Entsuah; Evan Tzanis; Naomi M Simon; Ying Zhang
Journal:  Psychopharmacology (Berl)       Date:  2007-06-23       Impact factor: 4.530

Review 9.  Diagnosis and treatment of agoraphobia with panic disorder.

Authors:  Giulio Perugi; Franco Frare; Cristina Toni
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 10.  [Early detection and treatment of panic disorder with or without agoraphobia: update].

Authors:  Guillaume Foldes-Busque; André Marchand; Pierre Landry
Journal:  Can Fam Physician       Date:  2007-10       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.